These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 9636541)
1. Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation. Charpentier B; Thervet E Transplant Proc; 1998 Jun; 30(4):1331-2. PubMed ID: 9636541 [No Abstract] [Full Text] [Related]
2. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Vincenti F; Nashan B; Light S Transplant Proc; 1998 Aug; 30(5):2155-8. PubMed ID: 9723424 [No Abstract] [Full Text] [Related]
3. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Nashan B; Light S; Hardie IR; Lin A; Johnson JR Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806 [TBL] [Abstract][Full Text] [Related]
4. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation. Vincenti F Transplant Proc; 1999 Sep; 31(6):2206-7. PubMed ID: 10500546 [No Abstract] [Full Text] [Related]
5. Daclizumab to prevent rejection after cardiac transplantation. Hershberger RE; Starling RC; Eisen HJ; Bergh CH; Kormos RL; Love RB; Van Bakel A; Gordon RD; Popat R; Cockey L; Mamelok RD N Engl J Med; 2005 Jun; 352(26):2705-13. PubMed ID: 15987919 [TBL] [Abstract][Full Text] [Related]
6. Can antibody prophylaxis allow sparing of other immunosuppressives? Vincenti F; Grinyo J; Ramos E; Nashan B; Stuart F; Kuypers D; Brattstrom C; Cho S; Ekberg H; Johnson R Transplant Proc; 1999; 31(1-2):1246-8. PubMed ID: 10083557 [No Abstract] [Full Text] [Related]
7. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F; Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447 [TBL] [Abstract][Full Text] [Related]
8. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Bumgardner GL; Ramos E; Lin A; Vincenti F; Transplantation; 2001 Aug; 72(4):642-7. PubMed ID: 11544424 [TBL] [Abstract][Full Text] [Related]
9. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups. Ekberg H; Bäckman L; Tufveson G; Tydén G Transplant Proc; 1999; 31(1-2):267-8. PubMed ID: 10083102 [No Abstract] [Full Text] [Related]
10. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection. Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505 [No Abstract] [Full Text] [Related]
11. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Wiseman LR; Faulds D Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817 [TBL] [Abstract][Full Text] [Related]
14. Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation. Poorrezagholi F; Einollahi B; Firoozan A; Nafar M; Yadegari H; Moghaddam SM; Simforoosh N; Basiri A; Farhangi S Transplant Proc; 2003 Nov; 35(7):2735-6. PubMed ID: 14612098 [No Abstract] [Full Text] [Related]
15. The role of newer monoclonal antibodies in renal transplantation. Vincenti F Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163 [No Abstract] [Full Text] [Related]
16. Daclizumab to prevent acute rejection in renal transplantation. Abramowicz D N Engl J Med; 1998 Jun; 338(23):1700-1. PubMed ID: 9616069 [No Abstract] [Full Text] [Related]
17. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788 [TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. Hengster P; Pescovitz MD; Hyatt D; Margreiter R Transplantation; 1999 Jul; 68(2):310-3. PubMed ID: 10440409 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation. Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Spasovski G; Sikole A; Paneva-Masin J Transplant Proc; 2001; 33(7-8):3203-4. PubMed ID: 11750374 [No Abstract] [Full Text] [Related]